Answers are grounded in this paper and cite their sources.
exist. This review suggests that the positive effects of platelet-rich plasma were less significant in clinical trials compared with the in vitro and in vivo experimental studies; therefore, it should be highlighted that platelet-rich plasma should not be considered as the first line of treatment in clinics because there is still a lack of evidence demonstrating that the administration of plateletrich plasma is an effective method to restore the quality and integrity of the injured tissues. Conclusion Platelet-rich plasma has some beneficial effects, especially at preclinical level. Most in vitro and in vivo animal studies used allologous forms of platelet-rich plasma, and the results confirmed the efficacy of platelet-rich plasma in soft and hard connective tissue healing in different animal species. In general, platelet-rich plasma is an effective conservative treatment without the complications and cost of surgery, and with moderate success of resolving various musculoskeletal conditions; however, it should not be placed in the first line of treatment modality because it is almost effective in the short term. Future clinical trial studies should be designed to test the real efficacy of platelet-rich plasma in a more standard manner.
No takes yet. Share an insight, caveat, or question.
Moshiri et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: